Search

Displaying results 3751 - 3760 of 10000 in total
  1. Drug

    Zaltoprofen

    go.drugbank.com/drugs/DB06737
    Investigational

    A non-steroidal anti-inflammatory drug approved for use in Japan in 1993.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  2. Target

    Serine/threonine-protein kinase 17B

    go.drugbank.com/bio_entities/BE0004328
    TargetHumans

    Phosphorylates myosin light chains (By similarity). Acts as a positive regulator of apoptosis

    Synonyms: DAP kinase-related apoptosis-inducing protein kinase 2
  3. Target

    Serine/threonine-protein kinase 17A

    go.drugbank.com/bio_entities/BE0009543
    TargetHumans

    Acts as a positive regulator of apoptosis. Also acts as a regulator of cellular reactive oxygen species

    Synonyms: DAP kinase-related apoptosis-inducing protein kinase 1
  4. Target

    Sodium-dependent dopamine transporter

    go.drugbank.com/bio_entities/BE0009676
    TransporterTargetMouse

    Mediates sodium- and chloride-dependent transport of dopamine (PubMed:10375632, PubMed:12606774). Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). Regulator of light-...

    Synonyms: Dat, DA transporter
  5. Drug

    Interferon Gamma

    go.drugbank.com/drugs/DB15753
    Investigational

    The interferon is primarily produced by activated T lymphocytes and natural killer cells.

  6. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

  7. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    Landiolol is a rapid-acting beta (β)-1 adrenergic receptor blocker that blocks the positive chronotropic effect of the beta-1 selective agonist norepinephrine. It works to reduce the heart rate, myocardial contractility, and conduction v...

  8. Drug

    Ciltacabtagene autoleucel

    go.drugbank.com/drugs/DB16738
    ApprovedInvestigational

    It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000,[L40749] and is variable in its presentation - some patients may remain entirely asymptomatic, while others may experience … [A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744]

  9. Drug

    Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB16923
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  10. Drug

    Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB18750
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen